The 2017 ESMO Congress wraps up on Tuesday in Madrid, Spain. On Monday, Jefferies issued a handful of flash notes related to companies presenting at the conference.
Here’s a breakdown of the highlights.
Five Prime Therapeutics
Five Prime Therapeutics Inc FPRX 0.28% reported positive data on its Phase I trials of FP-1039 in treatment of mesothelioma.
“Currently we do not include FP-1039 in our valuation; thus, if successfully developed, it would provide upside,” analyst Eun Yangwrote.
Bristol-Myers Squibb
Analyst Jeffrey Holford said new data on Bristol-Myers Squibb Co BMY 0.05%’s CM-214 suggests the market is prematurely writing off Yervoy.
“We see the CM-214 data driving a new indication and growth for Yervoy, helping to support our above consensus 2021E revenue estimate of $3.1bn vs. consensus of $1.8bn,” Holford wrote.
Eli Lilly
Holford said early indications suggest Eli Lilly and Co LLY 0.7% breast cancer treatment drug Abema could be the best in its class in terms of efficacy, but more data will be needed to support the initial findings.
“We see room for upside against our own and consensus estimates for Abema and have previously estimated that this could increase mid-term EPS and valuation for LLY by c3%-5%,” he wrote.
Array Biopharma
Array Biopharma Inc ARRY 1.31% reported some positive safety data from its ongoing Phase III BEACON trial. Yang said the new data suggests major potential for Array’s melanoma combination treatment.
“Aside from potential bini/enco approval by ~mid-2018 in somewhat crowded melanoma market, its combo potential in unmet CRC indication with limited competition & ~$1B market size represents likely upside, if successful,” Yang wrote.
Price Targets And Ratings
Jefferies maintains…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
